Rebonato Micol, Pilati Mara, Milani Sophie Malekzadeh, Bonnet Damien, Pascall Emma, Jones Matthew, Betrian Pedro, Bianco Lisa, Lucron Hugues, Hascoet Sebastien, Baruteau Alban-Elouen, Giugno Luca, Butera Gianfranco
Department of Pediatric Cardiology, Cardiac Surgery and Heart Lung Transplantation, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Centre de Référence Malformations Cardiaques Congénitales Complexes-M3C, Hôpital Universitaire Necker Enfants Malades, F-75015 Paris, France.
J Cardiovasc Dev Dis. 2024 Jun 25;11(7):192. doi: 10.3390/jcdd11070192.
Stent implantation has become the preferred method of treatment for treating vessel stenosis in congenital heart diseases. The availability of covered stents may decrease complications and have an important role in the management of patients with complex anatomy.
This study aims to evaluate the feasibility and safety of the pre-mounted cobalt-chromium stent-graft-covered ePTFE Aortic BeGraft in a broad spectrum of vascular lesions.
This is a multicenter retrospective results analysis of 107 implanted BeGraft stents between 2016 and 2022 in six different European centers.
One hundred and four patients with a mean age of thirteen years (range 1-70 years) and with the body weight of 56.5 kg (range 11-115 kg) underwent the BeGraft stent implantation. Stents were implanted in the following conditions: aortic coarctation (74 patients), RVOT dysfunction (12 patients), Fontan circulation (7 patients), and miscellaneous (11 subjects with complex CHD). All the stents were implanted successfully. The median stent diameter was 16 mm (range 7-24 mm), and the median length was 39 mm (range 19-49 mm). Major complications occurred in five subjects (4.7%). During a median follow-up of fourteen (1-70) months, stents' re-dilatation was performed in five patients.
The BeGraft stent can be used safely and effectively in a wide spectrum of congenital heart diseases. Whether these good results will be stable in the longer term still needs to be investigated in a follow-up given its recent introduction into clinical practice, in particular regarding stent fracture or neointimal proliferation.
支架植入已成为治疗先天性心脏病血管狭窄的首选方法。覆膜支架的应用可能会减少并发症，并在复杂解剖结构患者的管理中发挥重要作用。
本研究旨在评估预装钴铬覆膜支架ePTFE主动脉BeGraft在广泛血管病变中的可行性和安全性。
这是一项对2016年至2022年期间在六个不同欧洲中心植入的107个BeGraft支架进行的多中心回顾性结果分析。
104例患者接受了BeGraft支架植入，平均年龄13岁（范围1 - 70岁），体重56.5 kg（范围11 - 115 kg）。支架植入情况如下：主动脉缩窄（74例）、右心室流出道功能障碍（12例）、Fontan循环（7例）以及其他情况（11例复杂先天性心脏病患者）。所有支架均成功植入。支架中位直径为16 mm（范围7 - 24 mm），中位长度为39 mm（范围19 - 49 mm）。5例患者（4.7%）发生了主要并发症。在中位随访14（1 - 70）个月期间，5例患者进行了支架再扩张。
BeGraft支架可安全有效地用于广泛的先天性心脏病。鉴于其最近才引入临床实践，这些良好结果在长期是否稳定仍需在随访中进行研究，特别是关于支架断裂或新生内膜增生方面。
